Generalizability of ORIENT-11 trial results to a USstandard-of-care cohort with advanced non-small-cell lung cancer.

Abstract

Aim: This retrospective study estimated efficacy and safety of sintilimab+pemetrexed +platinum (SPP) versus placebo+pemetrexed+platinum (PPP)in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient's contribution to ORIENT-11 data based on characteristics of a targetUS population. Materials & methods: The targetUS population (n=557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weightsfor ORIENT-11 patients (n=397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamousNSCLC.